The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.

Moderna’s COVID-19 vaccine has received full approval from the US Food and Drug Administration (FDA) for use in children with medical conditions that put them at higher risk of severe illness.